Start your intake Dosing is a decision, not a lookup LIP-C dosing is set by a prescribing provider who weighs the indication, your individual factors, and how you tolerate the compound
Importantly, semglutides approval for MASH marks a watershed moment as it is the second ever MASH-specific therapy to be approved, and the first GLP-1 receptor antagonist, giving it momentum to significantly disrupt the MASH treatment market
These two ideas are not mutually exclusive
Clinicians should engage patients in shared decision-making regarding treatment duration, considering individual response, tolerability, cost, and patient preferences
This makes sense because BPC-157 naturally exists in your stomach juices to help repair the gut lining
Here is how we frame it for patients at Perfect B